Compare · BSX vs NSPR
BSX vs NSPR
Side-by-side comparison of Boston Scientific Corporation (BSX) and InspireMD Inc. (NSPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NSPR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.39B, about 3574.2x NSPR ($20.3M).
- Over the past year, BSX is down 51.3% and NSPR is down 67.1% - BSX leads by 15.8 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 5 for NSPR).
- BSX has more recent analyst coverage (25 ratings vs 1 for NSPR).
- Company
- Boston Scientific Corporation
- InspireMD Inc.
- Price
- $48.71+0.31%
- $0.81-9.41%
- Market cap
- $72.39B
- $20.3M
- 1M return
- -13.91%
- -30.33%
- 1Y return
- -51.31%
- -67.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 12
- 5
- Recent ratings
- 25
- 1
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
InspireMD Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest NSPR
- InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
- InspireMD Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Stuka Paul bought $17,500 worth of shares (20,000 units at $0.88), increasing direct ownership by 3% to 667,871 units (SEC Form 4)
- InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Commercial Officer Gleason Shane Thomas sold $189,594 worth of shares (85,295 units at $2.22), decreasing direct ownership by 7% to 1,053,882 units (SEC Form 4) (for tax liability)
- Director Stuka Paul bought $17,325 worth of shares (15,000 units at $1.16), increasing direct ownership by 2% to 647,871 units (SEC Form 4)
- CEO and President Slosman Marvin bought $25,200 worth of shares (21,000 units at $1.20), increasing direct ownership by 0.59% to 3,556,658 units (SEC Form 4)
- Amendment: Director Stuka Paul bought $88,026 worth of shares (75,626 units at $1.16), increasing direct ownership by 14% to 632,871 units (SEC Form 4)
- Director Stuka Paul bought $88,026 worth of shares (75,626 units at $1.16), increasing direct ownership by 14% to 632,871 units (SEC Form 4)
- Director Ward Scott R. bought $102,638 worth of shares (89,250 units at $1.15), increasing direct ownership by 60% to 237,096 units (SEC Form 4)